Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)
Karim Chamie, MD, presents the case of a 60-year-old patient with stage 3A muscle-invasive bladder cancer (MIBC) and explains her risk of disease recurrence and whether the case is similar to the patients he typically sees in his clinical practice.
EP: 1.Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)
EP: 2.Determining Cisplatin Eligibility for Patients with MIBC
EP: 3.Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy
EP: 4.Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology
EP: 5.Case 2 Presentation: A 77-Year-Old Man With MIBC
EP: 6.Unmet Needs and Clinical Challenges in the Management of MIBC
EP: 7.Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC
EP: 8.Clinical Pearls for Community Urologists Treating Patients with MIBC
FDA accepts resubmission of BLA for N-803 in NMIBC
October 26th 2023The FDA has accepted a resubmitted biologics license application for N-803 for use in combination with BCG for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
